VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2022 | Epilepsy in adults with neurodevelopmental disabilities: epidemiology & considerations

Christian Brandt, MD, Bielefeld University, Medical School, Bielefeld, Germany, discusses the differences in epidemiology in adult epilepsy patients with intellectual and neurodevelopmental disabilities (NDDs) and important considerations when treating these patients. The prevalence of epilepsy is much higher in individuals with NDDs than in the general population, and it depends on the degree of impairment: patient groups with more severe intellectual disabilities have a higher prevalence of epilepsy. Since patients with epilepsy and NDDs have special needs, a careful approach is needed when working with this patient population. Clinical experience has indicated that patients with NDDs are more sensitive to adverse events of antiseizure medications, making it essential to closely monitor the tolerability of those drugs in patients with NDDs. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.


Honoraria for speaking or consulting activities from Angelini/Arvelle, Eisai, Equilibre, GW Pharmaceuticals, Johnson&Johnson, Marinus, UCB Pharma, Xenon and Zogenix